# CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

> **NCT01206036** · PHASE1,PHASE2 · COMPLETED · sponsor: **Central European Society for Anticancer Drug Research** · enrollment: 19 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01206036
- **Lead sponsor:** Central European Society for Anticancer Drug Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-09
- **Final completion:** 2015-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206036, "CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01206036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*